-
EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function Cancer Cell (IF 48.8) Pub Date : 2024-12-05 Yusuke Isshiki, Xi Chen, Matt Teater, Ioannis Karagiannidis, Henna Nam, Winson Cai, Cem Meydan, Min Xia, Hao Shen, Johana Gutierrez, Vigneshwari Easwar Kumar, Sebastián E. Carrasco, Madhu M. Ouseph, Samuel Yamshon, Peter Martin, Ofir Griess, Efrat Shema, Patrizia Porazzi, Marco Ruella, Renier J. Brentjens, Wendy Béguelin
-
Mannose metabolism reshapes T cell differentiation to enhance anti-tumor immunity Cancer Cell (IF 48.8) Pub Date : 2024-12-05 Yajing Qiu, Yapeng Su, Ermei Xie, Hongcheng Cheng, Jing Du, Yue Xu, Xiaoli Pan, Zhe Wang, Daniel G. Chen, Hong Zhu, Philip D. Greenberg, Guideng Li
-
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer Cancer Cell (IF 48.8) Pub Date : 2024-11-21 George Seed, Nick Beije, Wei Yuan, Claudia Bertan, Jane Goodall, Arian Lundberg, Matthew Tyler, Ines Figueiredo, Rita Pereira, Chloe Baker, Denisa Bogdan, Lewis Gallagher, Jan-Phillipp Cieslik, Semini Greening, Maryou Lambros, Rui Neves, Lorena Magraner-Pardo, Gemma Fowler, Berni Ebbs, Susana Miranda, Penny Flohr, Diletta Bianchini, Pasquale Rescigno, Nuria Porta, Emma Hall, Bora Gurel, Nina Tunariu
-
Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade Cancer Cell (IF 48.8) Pub Date : 2024-11-21 Habib Hamidi, Yasin Senbabaoglu, Niha Beig, Juliette Roels, Cyrus Manuel, Xiangnan Guan, Hartmut Koeppen, Zoe June Assaf, Barzin Y. Nabet, Adrian Waddell, Kobe Yuen, Sophia Maund, Ethan Sokol, Jennifer M. Giltnane, Amber Schedlbauer, Eloisa Fuentes, James D. Cowan, Edward E. Kadel III, Viraj Degaonkar, Alexander Andreev-Drakhlin, Patrick Williams, Corey Carter, Suyasha Gupta, Elizabeth Steinberg, Yohann
-
Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation Cancer Cell (IF 48.8) Pub Date : 2024-11-21 David Hsiehchen, Andrew Elliott, Joanne Xiu, Andreas Seeber, Wafik El-Deiry, Emmanuel S. Antonarakis, Stephanie L. Graff, Michael J. Hall, Hossein Borghaei, Dave S.B. Hoon, Stephen V. Liu, Patrick C. Ma, Rana R. McKay, Trisha Wise-Draper, John Marshall, George W. Sledge, David Spetzler, Hao Zhu
Section snippets Main textCancers are conventionally classified as “hot” tumors that are associated with high tumor mutation burdens (TMBs) and tumor-infiltrating immune cells or “cold” tumors associated with a dearth of neoantigens and immune cell exclusion.1 This dichotomy is frequently used to define the degree of pre-existing immune cell reactivity within the tumor microenvironment and has been
-
Interleukin-1α release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity Cancer Cell (IF 48.8) Pub Date : 2024-11-21 Kay Hänggi, Jie Li, Achintyan Gangadharan, Xiaoxian Liu, Daiana P. Celias, Olabisi Osunmakinde, Aysenur Keske, Joshua Davis, Faiz Ahmad, Auriane Giron, Carmen M. Anadon, Alycia Gardner, David G. DeNardo, Timothy I. Shaw, Amer A. Beg, Xiaoqing Yu, Brian Ruffell
-
Unraveling the tumor-initiating cells in hepatocellular carcinoma Cancer Cell (IF 48.8) Pub Date : 2024-11-21 Yu Man Tsui, Daniel Wai-Hung Ho, Irene Oi-Lin Ng
Aggressive features of hepatocellular carcinoma (HCC) are highly related to liver tumor-initiating cells (TICs), which are heterogeneous and plastic. In this issue of Cancer Cell, Yang et al. reveal the ability of CD49f-high TICs in shaping the tumor immunosuppressive microenvironment in HCC.
-
Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma Cancer Cell (IF 48.8) Pub Date : 2024-11-14 Chun-Xiang Huang, Xiang-Ming Lao, Xu-Yan Wang, Yi-Zheng Ren, Yi-Tong Lu, Wei Shi, Ying-Zhe Wang, Cai-Yuan Wu, Li Xu, Min-Shan Chen, Qiang Gao, Lianxin Liu, Yuan Wei, Dong-Ming Kuang
-
Itaconate promotes an unexpected tumor immune escape mechanism Cancer Cell (IF 48.8) Pub Date : 2024-11-14 Lara Haase, Christian Frezza
Itaconate is a metabolite produced by macrophages upon infection and acts as an antimicrobial molecule. In this issue of Cancer Cell, Lin et al. find that itaconate produced by tumor-associated macrophages is taken up by cancer cells via the transporter solute carrier family 13 member 3 (SLC13A3), promoting resistance to immune checkpoint inhibitors.
-
In vivo models of subclonal oncogenesis and dependency in hematopoietic malignancy Cancer Cell (IF 48.8) Pub Date : 2024-11-11 Robert L. Bowman, Andrew J. Dunbar, Tanmay Mishra, Wenbin Xiao, Michael R. Waarts, Inés Fernández Maestre, Shira E. Eisman, Louise Cai, Shoron Mowla, Nisargbhai Shah, Angela Youn, Laura Bennett, Suean Fontenard, Shreeya Gounder, Anushka Gandhi, Michael Bowman, Kavi O’Connor, Zachary Zaroogian, Pablo Sánchez-Vela, Anthony R. Martinez Benitez, Ross L. Levine
-
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion Cancer Cell (IF 48.8) Pub Date : 2024-11-11 Rei Kudo, Anton Safonov, Catherine Jones, Enrico Moiso, Jonathan R. Dry, Hong Shao, Sharanya Nag, Edaise M. da Silva, Selma Yeni Yildirim, Qing Li, Elizabeth O’Connell, Payal Patel, Marie Will, Atsushi Fushimi, Marimar Benitez, Martina Bradic, Li Fan, Harikrishna Nakshatri, Dhivya R. Sudhan, Christopher R. Denz, Sarat Chandarlapaty
(Cancer Cell 42, 1919–1935.e9; November 11, 2024)
-
Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance Cancer Cell (IF 48.8) Pub Date : 2024-11-07 Heng Lin, Kole Tison, Yuheng Du, Paul Kirchhoff, Chan Kim, Weichao Wang, Hannah Yang, Michael Pitter, Jiali Yu, Peng Liao, Jiajia Zhou, Linda Vatan, Sara Grove, Shuang Wei, Thomas Vigil, Yatrik M. Shah, Richard Mortensen, Ilona Kryczek, Lana Garmire, Jwala P. Sivaccumar, Ashwin Kumar Ramesh, Ningyan Zhang, Zhiqiang An, Shaomeng Wang, Weiping Zou
-
Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy Cancer Cell (IF 48.8) Pub Date : 2024-11-07 Chen Yang, Haigang Geng, Xupeng Yang, Shuyi Ji, Zhicheng Liu, Hao Feng, Qian Li, Tangansu Zhang, Sisi Zhang, Xuhui Ma, Chuchen Zhu, Nuo Xu, Yuhan Xia, Yan Li, Hongye Wang, Chune Yu, Shangce Du, Beiping Miao, Lei Xu, Hui Wang, Ying Cao, Botai Li, Lili Zhu, Xiangyu Tang, Haoyu Zhang, Chunchao Zhu, Zhao Huang, Chao Leng, Haiyan Hu, Xiaoping Chen, Shengxian Yuan, Guangzhi Jin, René Bernards, Chong Sun
-
Intratumoral vidutolimod in combination with PD-1 blockade in locoregionally advanced melanoma Cancer Cell (IF 48.8) Pub Date : 2024-10-31 James W. Smithy, Michael A. Postow
Combinatorial immunotherapy may improve the efficacy of neoadjuvant checkpoint inhibitors in locoregionally advanced melanoma. In this issue of Cancer Cell, Davar and colleagues report a promising phase 2 neoadjuvant trial of the TLR9 agonist vidutolimod in combination with nivolumab. Analyses suggest a unique myeloid expression signature is associated with response.
-
Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial Cancer Cell (IF 48.8) Pub Date : 2024-10-31 Diwakar Davar, Robert M. Morrison, Amiran K. Dzutsev, Arivarasan Karunamurthy, Joe-Marc Chauvin, Florent Amatore, Julie S. Deutsch, Rodrigo X. Das Neves, Richard R. Rodrigues, John A. McCulloch, Hong Wang, Douglas J. Hartman, Jonathan H. Badger, Miriam R. Fernandes, Yulong Bai, Jie Sun, Alicia M. Cole, Poonam Aggarwal, Jennifer R. Fang, Christopher Deitrick, Hassane M. Zarour
-
Fertility outcomes post immune checkpoint inhibitor exposure Cancer Cell (IF 48.8) Pub Date : 2024-10-31 Emily C. Harrold, Martinique Ogle, Erin O’Brien, Callahan Wilde, Jenna Sinopoli, Jill Weiss, Lauren Martino, Anne Casson, Hey-Joo Kang, Michael Postow, Andrea Cercek
Harrold et al. evaluate the fertility impact of checkpoint inhibitor blockade (ICB), demonstrating that unlike in utero exposure, post-exposure conception appears to result in uncomplicated pregnancies and healthy progeny. They demonstrate contemporaneous monitoring of temporal female hormonal fluctuations before, on, and post ICB exposure and prior to successful embryo implantation.
-
Targeting DLK1 in neuroblastoma Cancer Cell (IF 48.8) Pub Date : 2024-10-31 John Anderson
An ideal cell surface target has ubiquitously high cancer expression, absence from healthy tissues, and an essential role cancer initiation and/or maintenance. In this issue of Cancer Cell, Hamilton et al. combine proteomics, transcriptomics, epigenomics, and dependency databases to identify DLK1, a novel immunotherapeutic target for neuroblastoma.
-
Finding the right friends: Stromal composition influences TLS formation in ovarian cancer Cancer Cell (IF 48.8) Pub Date : 2024-10-31 Lloyd Bod
In this issue of Cancer Cell, MacFawn et al. reveal that tertiary lymphoid structures (TLSs) in high-grade serous ovarian cancer (HGSOC) vary significantly by anatomical site. They highlight a distinct stromal composition associated with TLS formation, with cancer-educated mesenchymal stem cells (CA-MSCs) inversely linked to TLS activity and patient prognosis.
-
GDF15 research from bench to bedside Cancer Cell (IF 48.8) Pub Date : 2024-10-24 Samuel N. Breit, David A. Brown, Vicky W.W. Tsai
Pre-clinical data suggest that increased circulating growth differentiation factor 15 (GDF15) is a cause of both anorexia/cachexia syndromes and hyperemesis gravidarum in pregnancy, serious conditions with no highly effective treatment. A phase 2 study of a therapeutic GDF15 monoclonal antibody in the New England Journal of Medicine suggests that effective treatment of anorexia/cachexia in cancer may
-
A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma Cancer Cell (IF 48.8) Pub Date : 2024-10-24 Amber K. Hamilton, Alexander B. Radaoui, Matthew Tsang, Daniel Martinez, Karina L. Conkrite, Khushbu Patel, Simone Sidoli, Alberto Delaidelli, Apexa Modi, Jo Lynne Rokita, Maria V. Lane, Nicholas Hartnett, Raphael D. Lopez, Bo Zhang, Chuwei Zhong, Brian Ennis, Daniel P. Miller, Miguel A. Brown, Komal S. Rathi, Pichai Raman, Sharon J. Diskin
-
Integrating priorities at the intersection of cancer and neuroscience Cancer Cell (IF 48.8) Pub Date : 2024-10-17 William L. Hwang, Ella N. Perrault, Alexander Birbrair, Brandi J. Mattson, David H. Gutmann, Donald J. Mabbott, Edna Cukierman, Elizabeth A. Repasky, Erica K. Sloan, Hui Zong, Ihsan Ekin Demir, Jami L. Saloman, Jeremy C. Borniger, Jian Hu, Jorg Dietrich, Joshua J. Breunig, Kaan Çifcibaşı, Khalil Ali Ahmad Kasm, Manuel Valiente, Max Wintermark, Moran Amit
Cancer neuroscience is a rapidly growing multidisciplinary field that conceptualizes tumors as tissues fully integrated into the nervous system. Recognizing the complexity and challenges in this field is of fundamental importance to achieving the goal of translational impact for cancer patients. Our commentary highlights key scientific priorities, optimal training settings, and roadblocks to translating
-
IL-1 signaling in aging and cancer: An inflammaging feedback loop unveiled Cancer Cell (IF 48.8) Pub Date : 2024-10-17 Mingyong Liu, Bo Zhu, Qi-Jing Li
In a Science paper, Park et al. identified interleukin (IL)-1α as a key driver of positive feedback in inflammaging, linking aging-associated downregulation of DNMT3A to increased IL-1α production in lung myeloid cells. This triggers emergency myelopoiesis in the bone marrow, amplifying myeloid-mediated intratumoral immunosuppression for tumor progression in aged mice.
-
Overcoming tyrosine kinase inhibitor resistance in lung cancer brain metastasis with CTLA4 blockade Cancer Cell (IF 48.8) Pub Date : 2024-10-17 Minjie Fu, Jiaxu Zhao, Licheng Zhang, Zhewei Sheng, Xiaohui Li, Fufang Qiu, Yuan Feng, Muyuan You, Hao Xu, Jinsen Zhang, Rui Zeng, Yang Huang, Cheng Li, Wenhan Chen, Zheng Chen, Haibao Peng, Longzhi Li, Yonghe Wu, Dan Ye, Yudan Chi, Ying Mao
-
B cell heterogeneity in cancer comes of age Cancer Cell (IF 48.8) Pub Date : 2024-10-14 Colleen Sturdevant, Yuliya Pylayeva-Gupta
The role of B cells in cancer remains incompletely understood. Three recent publications, including a study by Fitzsimons et al. in this issue of Cancer Cell,1 use single-cell RNA sequencing to define pan-cancer atlases of tumor-infiltrating B cell subsets, paving the way for profound advances in our understanding of B cell-dependent antitumor immunity.
-
A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: The Keystone-001 trial Cancer Cell (IF 48.8) Pub Date : 2024-10-14 Xiaobin Shang, Yongjie Xie, Jinpu Yu, Chen Zhang, Gang Zhao, Fei Liang, Liang Liu, Weihong Zhang, Runmei Li, Wenwen Yu, Jie Yue, Chuangui Chen, Xiaofeng Duan, Zhao Ma, Zuoyu Chen, Yanjuan Xiong, Fan Yang, Jianyu Xiao, Rui Zhang, Pengpeng Liu, Hongjing Jiang
-
A pan-cancer single-cell RNA-seq atlas of intratumoral B cells Cancer Cell (IF 48.8) Pub Date : 2024-10-14 Evelyn Fitzsimons, Danwen Qian, Andrei Enica, Krupa Thakkar, Marcellus Augustine, Samuel Gamble, James L. Reading, Kevin Litchfield
-
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion Cancer Cell (IF 48.8) Pub Date : 2024-10-10 Rei Kudo, Anton Safonov, Catherine Jones, Enrico Moiso, Jonathan R. Dry, Hong Shao, Sharanya Nag, Edaise M. da Silva, Selma Yeni Yildirim, Qing Li, Elizabeth O'Connell, Payal Patel, Marie Will, Atsushi Fushimi, Marimar Benitez, Martina Bradic, Li Fan, Harikrishna Nakshatri, Dhivya R. Sudhan, Christopher R. Denz, Sarat Chandarlapaty
-
Accelerated approvals: Early-phase success or premature authorization? Cancer Cell (IF 48.8) Pub Date : 2024-10-10 Xiangyun Mao, G. Caleb Alexander, Guanqiao Li
We compare the clinical trial success rates of products receiving US Food and Drug Administration (FDA) accelerated approval (AA) to those approved without using this pathway. Our findings raise important questions about how the AA pathway can best optimize early access to therapeutics that are ultimately proven safe and effective.
-
The activity of tertiary lymphoid structures in high grade serous ovarian cancer is governed by site, stroma, and cellular interactions Cancer Cell (IF 48.8) Pub Date : 2024-10-10 Ian P. MacFawn, Grant Magnon, Grace Gorecki, Sheryl Kunning, Rufiaat Rashid, Medard Ernest Kaiza, Huda Atiya, Ayana T. Ruffin, Sarah Taylor, T. Rinda Soong, Riyue Bao, Lan G. Coffman, Tullia C. Bruno
-
Lactylation in cancer: Current understanding and challenges Cancer Cell (IF 48.8) Pub Date : 2024-10-10 Hongde Li, Linchong Sun, Ping Gao, Hai Hu
Lactylation, a recently identified post-translational modification, has initially been linked to gene transcription regulation through epigenetic mechanisms. However, its role in tumorigenesis—whether as a major driver or a minor regulator—remains uncertain. Here, we summarize the current understanding of lactylation and discuss the inherent challenges in definitively attributing specific biological
-
The hallmarks of cancer immune evasion Cancer Cell (IF 48.8) Pub Date : 2024-10-10 Claudia Galassi, Timothy A. Chan, Ilio Vitale, Lorenzo Galluzzi
According to the widely accepted “three Es” model, the host immune system eliminates malignant cell precursors and contains microscopic neoplasms in a dynamic equilibrium, preventing cancer outgrowth until neoplastic cells acquire genetic or epigenetic alterations that enable immune escape. This immunoevasive phenotype originates from various mechanisms that can be classified under a novel “three Cs”
-
Midkine as a driver of age-related changes and increase in mammary tumorigenesis Cancer Cell (IF 48.8) Pub Date : 2024-10-03 Pengze Yan, Ernesto Rojas Jimenez, Zheqi Li, Triet Bui, Marco Seehawer, Jun Nishida, Pierre Foidart, Laura E. Stevens, Yingtian Xie, Miguel Munoz Gomez, So Yeon Park, Henry W. Long, Kornelia Polyak
-
Spatial oncology: Translating contextual biology to the clinic Cancer Cell (IF 48.8) Pub Date : 2024-10-03 Dennis Gong, Jeanna M. Arbesfeld-Qiu, Ella Perrault, Jung Woo Bae, William L. Hwang
Microscopic examination of cells in their tissue context has been the driving force behind diagnostic histopathology over the past two centuries. Recently, the rise of advanced molecular biomarkers identified through single cell profiling has increased our understanding of cellular heterogeneity in cancer but have yet to significantly impact clinical care. Spatial technologies integrating molecular
-
Spark in the darkness: Discovering action potentials in brain tumors Cancer Cell (IF 48.8) Pub Date : 2024-10-03 Nikolas Andreas Stevens, Nina Drewa, Varun Venkataramani
Gliomas exhibit significant molecular diversity and poor prognosis. In this issue of Cancer Cell, Curry et al. apply Patch-seq on human glioma samples uncovering hybrid cells with glial and neuronal features, capable of firing action potentials in isocitrate dehydrogenase mutant gliomas. These findings highlight the importance of neural features in tumor biology and progression.
-
Midkine links aging with breast cancer—A new predictor of cancer risk Cancer Cell (IF 48.8) Pub Date : 2024-10-03 Jane E. Visvader
Despite aging being one of the strongest risk factors for cancer, little is known about the biological mechanisms that promote tumor initiation. In this issue of Cancer Cell, Yan et al. address this fundamental question in the context of breast cancer and report that midkine is upregulated during the aging process and can promote tumorigenesis.
-
Universal and tissue-specific fibroblasts in chronic inflammation and cancer Cancer Cell (IF 48.8) Pub Date : 2024-09-26 Simon Koplev, Sarah A. Teichmann
In this issue of Cancer Cell, Gao et al. map fibroblast diversity across tumors and chronic inflammatory tissues. The authors uncover universal fibroblast subtypes such as LRRC15+ and MMP1+ myofibroblasts along with specialized tissue-specific subtypes. They reveal cellular roles of fibroblasts in immunosuppression through stromal niches and cell-cell interactions.
-
Architecture sets the path: Breast cancer subtypes differently shape the early brain metastatic niche Cancer Cell (IF 48.8) Pub Date : 2024-09-26 Menno Boon, Leila Akkari
The ability of disseminated cancer cells to colonize the brain is highly dependent on initial survival cues, often evoking early microenvironmental adaptations. In this issue of Cancer Cell, Gan et al. unveil disparate tumor architectures in early stage HER2+ breast cancer and triple-negative breast cancer brain metastases that shape stromal interactions, providing a rationale for subtype-dependent
-
Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer Cancer Cell (IF 48.8) Pub Date : 2024-09-19 Bianca Calì, Martina Troiani, Silvia Bressan, Giuseppe Attanasio, Sara Merler, Viola Moscarda, Simone Mosole, Elena Ricci, Christina Guo, Wei Yuan, Lewis Gallagher, Arian Lundberg, Ilona Bernett, Ines Figueiredo, Rydell Alvarez Arzola, Ernesto Bermudez Abreut, Mariantonietta D’Ambrosio, Nicolò Bancaro, Daniela Brina, Sara Zumerle, Andrea Alimonti
-
Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer Cancer Cell (IF 48.8) Pub Date : 2024-09-19 Xueliang Wang, Yi Fang, Wei Liang, Chi Chun Wong, Huanlong Qin, Yaohui Gao, Meinong Liang, Lei Song, Yongxin Zhang, Miao Fan, Chuanfa Liu, Harry Cheuk-Hay Lau, Lixia Xu, Xiaoxing Li, Wu Song, Junlin Wang, Na Wang, Tao Yang, Mengmiao Mo, Xiang Zhang, Jun Yu
-
Cross-tissue human fibroblast atlas reveals myofibroblast subtypes with distinct roles in immune modulation Cancer Cell (IF 48.8) Pub Date : 2024-09-19 Yang Gao, Jianan Li, Wenfeng Cheng, Tian Diao, Huilan Liu, Yufei Bo, Chang Liu, Wei Zhou, Minmin Chen, Yuanyuan Zhang, Zhihua Liu, Weidong Han, Rufu Chen, Jirun Peng, Linnan Zhu, Wenhong Hou, Zemin Zhang
-
Ovarian cancer metastasis: Looking beyond the surface Cancer Cell (IF 48.8) Pub Date : 2024-09-12 Emine Bayraktar, Sisy Chen, Sara Corvigno, Jinsong Liu, Anil K. Sood
Historically, ovarian cancer (OC) was thought to metastasize by surface-to-surface spread, but recent developments have yielded a new understanding of the paths of metastatic spread. Given the histologic and molecular heterogeneity of OC, we will focus on high-grade serous carcinoma (HGSC). Here, we provide a critical and more holistic view of the evidence supporting various routes of metastasis, including
-
From backstage to the spotlight: γδT cells in cancer Cancer Cell (IF 48.8) Pub Date : 2024-09-12 Robert Wiesheu, Seth B. Coffelt
γδT cells represent a group of immune cells that are understudied but whose utility has been recognized for cancer immunotherapy purposes. Recent studies have highlighted a critical role for these cells in tumor initiation, growth, and metastasis and revealed an increasingly complex biology of γδT cell subsets that is context and tissue specific. We discuss here how γδT cell subsets are regulated,
-
Distinct tumor architectures and microenvironments for the initiation of breast cancer metastasis in the brain Cancer Cell (IF 48.8) Pub Date : 2024-09-12 Siting Gan, Danilo G. Macalinao, Sayyed Hamed Shahoei, Lin Tian, Xin Jin, Harihar Basnet, Catherine Bibby, James T. Muller, Pranita Atri, Evan Seffar, Walid Chatila, Ali Karacay, Pharto Chanda, Anna-Katerina Hadjantonakis, Nikolaus Schultz, Edi Brogi, Tejus A. Bale, Nelson S. Moss, Rajmohan Murali, Dana Pe’er, Joan Massagué
-
Classifying cancer-associated fibroblasts—The good, the bad, and the target Cancer Cell (IF 48.8) Pub Date : 2024-09-09 Lena Cords, Natalie de Souza, Bernd Bodenmiller
Cancer-associated fibroblasts (CAFs) are heterogeneous and ubiquitous stromal cells within the tumor microenvironment (TME). Numerous CAF types have been described, typically using single-cell technologies such as single-cell RNA sequencing. There is no general classification system for CAFs, hampering their study and therapeutic targeting. We propose a simple CAF classification system based on single-cell
-
Assessing clonal changes in T cells over time following immunotherapy is a breeze with Cyclone Cancer Cell (IF 48.8) Pub Date : 2024-09-09 Anthony R. Cillo, John M. Kirkwood
Combination immunotherapy improves outcomes in metastatic melanoma, but the underlying mechanisms remain unclear. In this issue of Cancer Cell, Wang et al.1 report dynamics and transcriptional states of CD8+ T cell clones over time in patients treated with anti-PD-1, anti-CTLA-4, or a combination of the two. These findings have important implications for understanding and monitoring combination immunotherapy
-
Fibrotic response to anti-CSF-1R therapy potentiates glioblastoma recurrence Cancer Cell (IF 48.8) Pub Date : 2024-09-09 Spencer S. Watson, Anoek Zomer, Nadine Fournier, Joao Lourenco, Manfredo Quadroni, Agnieszka Chryplewicz, Sina Nassiri, Pauline Aubel, Simona Avanthay, Davide Croci, Erik Abels, Marike L.D. Broekman, Douglas Hanahan, Jason T. Huse, Roy T. Daniel, Monika E. Hegi, Krisztian Homicsko, Giulia Cossu, Andreas F. Hottinger, Johanna A. Joyce
-
Glioblastoma induces the recruitment and differentiation of dendritic-like “hybrid” neutrophils from skull bone marrow Cancer Cell (IF 48.8) Pub Date : 2024-09-09 Meeki Lad, Angad S. Beniwal, Saket Jain, Poojan Shukla, Venina Kalistratova, Jangham Jung, Sumedh S. Shah, Garima Yagnik, Atul Saha, Ankita Sati, Husam Babikir, Alan T. Nguyen, Sabraj Gill, Jennifer Rios, Jacob S. Young, Austin Lui, Diana Salha, Aaron Diaz, Manish K. Aghi
-
Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer Cancer Cell (IF 48.8) Pub Date : 2024-09-09 Jiachen Xu, Rui Wan, Yiran Cai, Shangli Cai, Lin Wu, Baolan Li, Jianchun Duan, Ying Cheng, Xiaoling Li, Xicheng Wang, Liang Han, Xiaohong Wu, Yun Fan, Yan Yu, Dongqing Lv, Jianhua Shi, Jianjin Huang, Shaozhang Zhou, Baohui Han, Guogui Sun, Qisen Guo, Youxin Ji, Xiaoli Zhu, Sheng Hu, Wei Zhang, Qiming Wang, Yuming Jia, Ziping Wang, Yong Song, Jingxun Wu, Meiqi Shi, Xingya Li, Zhigang Han, Yunpeng Liu
-
Integrated electrophysiological and genomic profiles of single cells reveal spiking tumor cells in human glioma Cancer Cell (IF 48.8) Pub Date : 2024-09-05 Rachel N. Curry, Qianqian Ma, Malcolm F. McDonald, Yeunjung Ko, Snigdha Srivastava, Pey-Shyuan Chin, Peihao He, Brittney Lozzi, Prazwal Athukuri, Junzhan Jing, Su Wang, Arif O. Harmanci, Benjamin Arenkiel, Xiaolong Jiang, Benjamin Deneen, Ganesh Rao, Akdes Serin Harmanci
-
GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant Cancer Cell (IF 48.8) Pub Date : 2024-09-03 Ilon Liu, Gustavo Alencastro Veiga Cruzeiro, Lynn Bjerke, Rebecca F. Rogers, Yura Grabovska, Alexander Beck, Alan Mackay, Tara Barron, Olivia A. Hack, Michael A. Quezada, Valeria Molinari, McKenzie L. Shaw, Marta Perez-Somarriba, Sara Temelso, Florence Raynaud, Ruth Ruddle, Eshini Panditharatna, Bernhard Englinger, Hafsa M. Mire, Li Jiang, Andrezza Nascimento, Jenna LaBelle, Rebecca Haase, Jacob Rozowsky
-
Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy Cancer Cell (IF 48.8) Pub Date : 2024-08-29 Christopher A. Eide, Diana Brewer, Tao Xie, Anna Reister Schultz, Samantha L. Savage, Serena Muratcioglu, Noah Merz, Richard D. Press, Thomas O’Hare, Thomas Jacob, Tania Q. Vu, Cristina E. Tognon, Tara A. Macey, John Kuriyan, Charalampos G. Kalodimos, Brian J. Druker
No Abstract
-
PD-1 blockade is a promising therapeutic addition to neoadjuvant chemoradiation in locally advanced rectal cancer Cancer Cell (IF 48.8) Pub Date : 2024-08-29 Ashwin Somasundaram, Hanna K. Sanoff
Neoadjuvant chemoradiotherapy has been a mainstay of the treatment of locally advanced rectal cancer. Programmed cell death protein 1 (PD-1) blockade therapy has demonstrated efficacy in combination with radiation. In this issue, Xiao et al. demonstrate promising efficacy with the addition of PD-1 blockade to neoadjuvant therapy for mismatch-repair proficient rectal cancer.
-
Cancer cell states: Lessons from ten years of single-cell RNA-sequencing of human tumors Cancer Cell (IF 48.8) Pub Date : 2024-08-29 Itay Tirosh, Mario L. Suva
Human tumors are intricate ecosystems composed of diverse genetic clones and malignant cell states that evolve in a complex tumor micro-environment. Single-cell RNA-sequencing (scRNA-seq) provides a compelling strategy to dissect this intricate biology and has enabled a revolution in our ability to understand tumor biology over the last ten years. Here we reflect on this first decade of scRNA-seq in
-
Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer Cancer Cell (IF 48.8) Pub Date : 2024-08-29 Caitlin A. McIntyre, Adrien Grimont, Jiwoon Park, Yinuo Meng, Whitney J. Sisso, Kenneth Seier, Gun Ho Jang, Henry Walch, Victoria G. Aveson, David J. Falvo, William B. Fall, Christopher W. Chan, Andrew Wenger, Brett L. Ecker, Alessandra Pulvirenti, Rebecca Gelfer, Maria Paz Zafra, Nikolaus Schultz, Wungki Park, Eileen M. O’Reilly, Shauna L. Houlihan, Alicia Alonso, Erika Hissong, George M. Church,
-
Precision oncology across the ages: Impact on children, adolescents, and young adults Cancer Cell (IF 48.8) Pub Date : 2024-08-29 Vivek Subbiah, Razelle Kurzrock
Precision oncology endeavors to tailor therapies based on individual patient and tumor characteristics. This rapidly evolving field has transformed cancer treatment across all age groups. In this commentary, we review the application of precision oncology across different age groups, specifically in children, adolescents, and young adults, and emphasize that precision medicine is age and tissue agnostic
-
The KRAS mutational spectrum and its clinical implications in pancreatic cancer Cancer Cell (IF 48.8) Pub Date : 2024-08-29 Luigi Perelli, Giannicola Genovese, Giulio F. Draetta
In this issue of Cancer Cell, McIntyre et al. show that specific mutations in the KRAS proto-oncogene shape clinical progression of pancreatic ductal adenocarcinoma (PDAC). Importantly, they find that the KRASG12R mutation is enriched in early-stage PDAC, and it is characterized by distinctly activated molecular programs.
-
Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells Cancer Cell (IF 48.8) Pub Date : 2024-08-29 Kevin Wang, Paulina Coutifaris, David Brocks, Guanning Wang, Tarek Azar, Sabrina Solis, Ajeya Nandi, Shaneaka Anderson, Nicholas Han, Sasikanth Manne, Evgeny Kiner, Chirag Sachar, Minke Lucas, Sangeeth George, Patrick K. Yan, Melanie W. Kier, Amy I. Laughlin, Shawn Kothari, Josephine Giles, Divij Mathew, Reem Ghinnagow, Cecile Alanio, Ahron Flowers, Wei Xu, Daniel J. Tenney, Xiaowei Xu, Ravi K. Amaravadi
-
Integrated single cell analysis reveals co-evolution of malignant B cells and tumor micro-environment in transformed follicular lymphoma Cancer Cell (IF 48.8) Pub Date : 2024-08-15 Clémentine Sarkozy, Shaocheng Wu, Katsuyoshi Takata, Tomohiro Aoki, Susana B. Neriah, Katy Milne, Talia Goodyear, Celia Strong, Tashi Rastogi, Laura K. Hilton, Daniel Lai, Laurie H. Sehn, Pedro Farinha, Brad H. Nelson, Andrew Weng, Marco Marra, David W. Scott, Jeffrey W. Craig, Christian Steidl, Andrew Roth
(Cancer Cell 42, 1003–1017.e1–e6; June 10, 2024)
-
Leading medulloblastoma to a differentiation end Cancer Cell (IF 48.8) Pub Date : 2024-08-12 Carolina Nör, Vijay Ramaswamy
Effective and less toxic therapies for medulloblastoma have proved to be highly elusive. In this issue of Cancer Cell, Yang et al. show that thyroid hormone treatment leads to the activation of neurogenic differentiation factor 1 (NeuroD1) and differentiation of medulloblastoma cells through reversing EZH2-mediated transcriptional repression of NeuroD1.
-
When playing the NK cell therapy card in glioblastoma, you can’t beat interleukin-21 Cancer Cell (IF 48.8) Pub Date : 2024-08-12 Nicholas D. Huntington
Glioblastoma is the most common brain cancer, with a 5-year survival rate of less than 10%. This grim prognosis highlights the urgent need for novel therapeutic approaches. In this issue of Cancer Cell, Shanley et al.1 report an innovative engineering strategy to supercharge NK cell immunity against glioblastoma.